Cancer Letters

Cancer Letters

Volume 193, Issue 2, 25 April 2003, Pages 183-188
Cancer Letters

Regulation of cell proliferation by induction of p21/WAF1 in rat bladder carcinoma cells using the Cre–loxP system

https://doi.org/10.1016/S0304-3835(03)00007-7Get rights and content

Abstract

p21/WAF1, a cyclin-dependent kinase inhibitory protein, functions as a tumor suppressor. Loss of p21/WAF1 expression has been reported to be an important prognostic predictor in several human malignancies, including bladder carcinomas. In this study, we induced p21/WAF1 using a Cre–loxP gene expression switching vector system in BC31 rat bladder carcinoma cells that feature p53 gene mutations. Cells in which p21/WAF1 was induced in nuclei were not labeled with BrdU and overall showed decreased cell proliferation, with increase in the G0–G1 population evident on flow cytometer analysis. The Cre treatment did not affect BC31 parental cells. These results show induction of p21/WAF1 can inhibit proliferation of tumor cells having p53 mutations, and could thus be applied as a potential therapy.

Introduction

p21/WAF1 is a cyclin-dependent kinase inhibitory protein [1] that regulates the cell cycle, potentially functioning as a tumor suppressor [2]. It is transcriptionally induced by p53 [2], the function of which is missing in a high percentage of human tumors [3], [4]. Many reports have documented alterations in the p53 gene in bladder carcinomas [5], [6], [7], [8]. In the absence of a functional p53 protein, expression of p21/WAF1 is often undetectable or present at only a very low level, and immunocytochemical studies have demonstrated a global decrease of p21/WAF1 expression in human tumors compared with normal tissues [9]. Moreover, loss of p21/WAF1 expression has been reported to be an important prognostic predictor in several human malignancies, including bladder carcinomas [3], [4], [10], [11]. Since it has been shown that p21/WAF1 expression can also be mediated through p53-independent pathways [7], [12], [13], [14], the possibility arises of overexpression applied for treatment of bladder carcinomas regardless of p53 alterations.

In this study we detected p53 gene mutations by performing PCR-SSCP analysis and direct sequencing in BC31 bladder carcinoma cells, established from a rat bladder carcinoma as previously reported [15]. Then, we induced expression of p21/WAF1 with the Cre–loxP system, which is able to regulate gene expression by on/off switching [16], [17]. Activation of the transgene flanked by a pair of loxP sites can be controlled on/off by using the Cre-producing recombinant adenovirus vector. This methodology is particularly useful in cases where there is difficulty in obtaining stable clones because of inhibition of cell proliferation by a targeted gene such as p21/WAF1.

Section snippets

BC31 cell culture

The rat BC31 cell line, established from a chemically-induced rat bladder transitional cell carcinoma [15], [18] was maintained in culture in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum under 5% CO2/95% air at 37 °C in a humidified incubator.

DNA Extraction, PCR-SSCP and direct sequencing

DNA samples were extracted by using Sepa Gene (Sanko Junyaku Co., Ltd, Tokyo). Primers were synthesized to amplify exons 5, 6, 7 and 8 according to published sequences [19]. The primer sequences were 5′-GATTCTTTCTCCTCTCCTAC-3′

p53 gene mutations in BC31 cells

We examined exons 5–8 for p53 gene mutations by PCR-SSCP and confirmed the results by direct sequencing of both strands. BC31 had mutations in codon 165 (exon 5, CAA→TAA) and codon 273 (exon 8, TGT→TGG). No wild type of p53 gene was detected in BC31.

p21/WAF1 protein induction with the Cre–loxP system in BC31 cells

We confirmed induction of p21/WAF1 expression by Cre treatment in the transfectants by Western blot analysis (Fig. 2). Levels of p21/WAF1 were found to be overexpressed in some transfectants treated with Cre compared to levels in the non-treated

Discussion

In the present study, we identified p53 mutations in BC31 cells and demonstrated that the cyclin dependent kinase inhibitor p21/WAF1 plays a very important role in reducing cell proliferation. p21/WAF1 is thought to regulate cell cycle events by binding directly to cyclin-dependent kinases and thus causing G1 arrest. p27/KIP1 is another cyclin-dependent kinase inhibitor and an association has been reported between loss of p21/WAF1 and p27/KIP1 expression and progression in a number of tumor

Acknowledgements

We would like to thank to Dr Izumi Saito for providing the Cre loxP gene expression switching vector (pCALNAL5) and the Cre recombinase producing adenovirus vector (AdexCre). This study was supported by a Grant-in-Aid for Cancer Research from the Society for Promotion of Pathology (Nagoya, Japan).

References (19)

  • W.S. el-Deiry et al.

    and B

    Vogelstein, WAF1, a potential mediator of p53 tumor suppression, Cell

    (1993)
  • A.R. Zlotta et al.

    and C.C. Schulman, Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy, J. Urol.

    (1999)
  • Y. Kanegae et al.

    and I

    Saito, Efficient gene activation system on mammalian cell chromosomes using recombinant adenovirus producing Cre recombinase, Gene

    (1996)
  • H. Hojo et al.

    and Y

    Hashimoto, Subcellular localization and characterization of interleukin-1 alpha produced by rat bladder cancer cells, Immunol. Lett.

    (1994)
  • Y. Xiong et al.

    and D

    Beach, p21 is a universal inhibitor of cyclin kinases, Nature

    (1993)
  • J.P. Stein et al.

    and R.J. Cote, Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer, J. Natl. Cancer Inst.

    (1998)
  • M. Migaldi et al.

    and G.P. Trentini, Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers, Clin. Cancer Res.

    (2000)
  • K. Fujimoto et al.

    and M

    Terada, Frequent association of p53 gene mutation in invasive bladder cancer, Cancer Res.

    (1992)
  • D. Sidransky et al.

    and.Identification of p53 gene mutations in bladder cancers and urine samples, Science

    (1991)
There are more references available in the full text version of this article.

Cited by (4)

View full text